Clinical Trial Update: Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sintilimab plus XELOX versus placebo plus XELOX as first-line treatment for gastric cancer; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Sintilimab (sintilimab)
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Gastric Cancer | Phase 3 | Status: COMPLETED